Daquiran (pramipexole)
- Region
- 🇪🇺 EU
- Active substance
- pramipexole
- Company
- Dr. Karl Thomae GmbH
- Status
- Withdrawn
- Therapeutic area
- Parkinson Disease
- EU approval
- Mon 27 Oct 1997
- Application
- EMEA/H/C/000135
- ATC
- N04BC05
- Official record
- www.ema.europa.eu
Indication
DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Mirapexin Authorised · Boehringer Ingelheim International GmbH
- 🇪🇺 Sifrol Authorised · Boehringer Ingelheim International GmbH
- 🇪🇺 Pramipexole Teva Authorised · Teva Pharma B.V.
- 🇪🇺 Oprymea Authorised · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 Pramipexole Accord Withdrawn · Accord Healthcare S.L.U.
Follow Daquiran
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.